.jpg)
CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy development
On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market for early-stage development of cell and gene therapies, which it said stymied its ability to grow.
On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market for early-stage development of cell and gene therapies, which it said stymied its ability to grow.
